FemTech is often framed as a market trend. In this episode of “Clinical Capital Conversations”, Dr. Peter M. Kovacs explains why it is actually a long-overdue clinical correction.

Together with Roswitha Verwer, Founder and CEO of “YON E”, and Muskaan Bhan, Chief Clinical Officer, this conversation explores why women were historically excluded from clinical trials, how biased data still shape healthcare AI, and why continuous measurement is changing medicine.

This episode is for investors, founders, and healthcare leaders who care about execution, responsibility, and long-term impact, not shortcuts.

Timecode:

00:00 Welcome and Introduction

00:50 Progress and Achievements in FemTech

02:16 Strategic Planning and Teamwork

05:18 Challenges in FemTech and AI Development

08:42 Importance of Continuous Data Tracking

12:49 Ethical Considerations and Long-Term Goals

16:20 FemTech Industry Trends and Future Outlook

20:29 Navigating Advisory Roles in a Regulated Era

20:48 The Rise of FemTech and Female Health Initiatives

22:38 Building a Supportive FemTech Community

23:19 Challenges in FemTech Investment

24:34 Investor Conversations and Strategies

30:21 The Importance of Team and Personal Connections

33:08 Future Plans and Closing Remarks

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Roswitha Verwer LinkedIn: https://www.linkedin.com/in/roswitha-verwer-b2b636137/

Roswitha Verwer Personal Website: https://www.roswithaverwer.com/

Dr. Muskaan Bhan: https://www.linkedin.com/in/dr-muskaan-bhan-9b7123120/

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs sits down with Roswitha Verwer (YONE) and Karoly Szanto to unpack what most investors miss in early-stage health innovation: execution is the moat.

YONE delivered the majority of a 12-month roadmap in 6 months. We break down how it happened, what systems made it possible, and why femtech fundraising is still biased even when the operating metrics are strong.

What we cover:

• How to build vendor communication into contracts and timelines

• Running a high-performance global team without losing control

• Meritocracy, KPIs, and having hard performance conversations with facts

• Why female founders and femtech still face access barriers to capital

• The gap stage problem in medtech funding, and why value-driven partners matter

• Why many accelerators create noise, not outcomes

• The next milestones for YONE, including the 600,000 co-investment raise and the seed round plan

This is a conversation for investors, founders, and operators who want clinical innovation that scales, de-risks, and reaches patients.

Timecode:

00:00 Introduction and Welcome

00:21 Achievements and Progress

01:38 Lessons for Startup Founders

02:56 Building a Strong Global Team

04:44 Handling Underperformance

09:36 Future Challenges and Milestones

13:28 Fundraising Challenges for FemTech

27:36 The Importance of Value-Driven Partnerships

31:29 Conclusion and Gratitude

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Roswitha Verwer: https://www.linkedin.com/in/roswitha-verwer-b2b636137/

Károly Szántó: https://www.linkedin.com/in/karolyszanto1/

This is a continuation of our main conversation on what it takes to turn medical innovation into scalable impact.

In this episode, Dr. Peter M. Kovacs sits down with Károly Szántó and Thijmen Meijer to unpack the co-investor question that determines everything in biotech and medtech.

If you are building or funding early-stage life sciences, this is the uncomfortable truth: the cap table is a governance system. The wrong co-investors can slow execution, distort milestones, and burn capital. The right co-investors create speed, trust, and real de-risk.

What we cover:

• Why investor labels matter less than incentives and behavior

• Skin in the game, and why it changes decision quality

• Two co-investor archetypes that create real synergy

• How family offices think, and why relationships and values come first

• Europe versus Asia: differences in investor mindset and culture

• Why smaller, domain-specific funds are gaining momentum

• Practical questions founders and investors should ask before partnering
  

Who this is for: Founders in biotech and medtech, healthcare VCs, family offices, corporate venture teams, private equity, and operators building clinical infrastructure.

Timecode:

00:00 Introduction to Key Stakeholders

00:22 Types of Co-Investors

01:09 Value Proposition and Commitment

02:10 Investor Specialization and Synergies

03:26 Role of Angel Investors

04:02 Corporate Venture Capital

04:44 Family Offices and Personal Touch

08:56 Challenges in Different Regions

09:32 Building Relationships with Investors

10:34 High Net Worth Individuals

18:02 Micro Funds and Emerging Managers

19:51 Conclusion and Future Outlook

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Károly Szántó: https://www.linkedin.com/in/karolyszanto1/

Thijmen Meijer: https://www.linkedin.com/in/thmnmr/

UniPrisma: https://uniprisma.com/

Europe has elite science. Asia has a capital. So why do so many European university spinouts never reach venture readiness or exits?

In this episode, Dr. Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer about the real gaps that block deep tech startups, especially in Central and Eastern Europe, and what a modern support model looks like.

What we cover:

• Why most spinouts never become VC fundable

• The commercialization gap between research and markets

• Mindset, team design, and why the founder is not always the CEO

• IP clarity and why it is the first gate to investability

• Milestones that remove ambiguity and build investor trust

• Smart money versus dumb money in biotech and medtech

• How to bridge Europe’s science with Asia’s capital through operators and partnerships
  

Key takeaway: funding is not the goal. Value creation is the goal.

Subscribe for more conversations at the crossroads of science and capital.

Timecode:

00:00 Introduction and Meeting the Guests

00:16 Challenges Faced by European Startups

04:44 The Importance of Mindset in Commercialization

07:43 Building Effective Teams for Startups

14:04 Investment Challenges and Opportunities

17:15 The Role of Clear Goals and Milestones

21:40 The Investor's Perspective

25:26 Introduction to Portfolio Companies

25:45 The Need for New Investment Models

26:05 Technological Boom and Efficiency

26:29 Building Companies for Impact

27:30 Challenges in Deep Tech Investment

27:50 Value-Driven Founders

29:12 Operational Models and Risk Mitigation

30:50 Identifying Good Partners

32:55 Scaling Up and Future Goals

33:43 Investor and Founder Dynamics

37:09 Cultural Differences in Startups

46:40 Lab Space and Resource Challenges

49:39 Networking and Collaboration

51:57 Preparing for Global Markets

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Károly Szántó: https://www.karolyszanto.com/

Thijmen Meijer: https://www.thijmenmeijer.com/

UniPrisma: https://uniprisma.com/

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs speaks with Károly Szántó about venture studios, calculated risk, and what it really takes to turn promising innovation into execution.

We cover:

• How a non-linear career becomes a competitive advantage

• Why focus beats speed in early-stage venture building

• The difference between high risk and calculated risk

• What university spinouts are missing, and how to fix it through market partnership

• How ecosystems change through examples, not speeches

• What investors should do diligence to avoid science-driven capital burn

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Timecode:

00:00 Introduction and Guest Welcome

00:26 Karoly's Career Journey

01:16 Discovering Sales and Business Development

03:46 Embracing Entrepreneurship

07:55 Building Uni Prisma Venture Studio

08:49 Venture Capital Experience

13:57 Focus on Healthcare and Impact

18:09 Challenges and Future Vision

22:49 Conclusion and Final Thoughts

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Károly Szántó: https://www.linkedin.com/in/karolyszanto1/

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Michaela Hrdlickova about Age Management and why workforce execution risk is one of the most overlooked variables in healthcare investing.

We explore how work ability is measured, why leadership quality drives performance, and how investors can protect long-duration returns by treating human capital as infrastructure.

This conversation is essential for biotech founders, healthcare investors, board members, and operators navigating long clinical timelines and execution complexity.

Subscribe for more conversations at the crossroads of science and capital.

Timecode:

00:00 Introduction to Misa Hrdlickova and Age Management

00:41 The Concept and History of Age Management

03:01 Implementing Age Management in Companies

05:50 Solutions and Processes for Age Management

14:07 Misa Hrdlickova's Background and Career Journey

21:24 Advice for Future Generations

23:09 Conclusion and Final Thoughts

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Michaela Hrdlickova: https://www.michaelahrdlickova.eu/

Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Ales Vavra, a former hedge fund manager known for exposing weaknesses in overhyped biotech companies. Together, they explore what investors often misunderstand about biotech risk, why due diligence fails, how AI is reshaping investment analysis, and the mindset required to survive the volatility of the sector.

If you invest in biotech, medtech, or clinical infrastructure, this conversation will challenge your assumptions and sharpen your thinking.

Topics covered:

• The psychology that misleads biotech investors

• Why execution risk matters more than scientific novelty

• How AI can support diligence without replacing expertise

• The danger of hype cycles in Alzheimer’s, longevity, and obesity

• Why diversification and discipline outperform intuition

• What separates resilient investors from speculative gamblers

Subscribe to Clinical Capital Conversations for more insights at the intersection of science and capital.

Timecode:

00:00 Introduction and Guest Background

01:44 Investment Strategies in Healthcare

03:13 Red Flags in Healthcare Investments

06:04 Role of AI in Investment Decisions

08:16 Advice for Healthcare Investors

12:01 Success Stories and Challenges

14:07 The Role of Sugar in Our Lives

14:55 Alcohol Consumption and Life Balance

15:43 The Hype and Reality of AI

18:40 Investment Challenges for Startups

21:48 Bitcoin and Long-Term Value

25:15 Personal Reflections and Future Outlook

26:17 Final Thoughts on Investment and Life

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Ales Vavra https://www.linkedin.com/in/ales-vavra-6423475/

Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

AI memory therapy is no longer a concept. It is here, clinically validated, and already helping dementia patients feel less lonely and more connected.

In this episode of Clinical Capital Conversations, Peter M. Kovacs speaks with Kompanion Care founder Peter Markus about Lilia, an AI-powered therapeutic platform that combines reminiscence therapy, family-generated memories, and digital biomarkers to deliver real clinical impact.

We explore:

• How personal loss shaped the company

• Why AI can scale proven psychotherapies

• How clinical validation creates trust

• Why reimbursement is the true growth path

• How digital biomarkers will transform early detection

If you want to understand where dementia care, digital therapeutics, and AI-driven monitoring are heading, this conversation is essential.

Timecode:

00:00 Introduction and Guest Introduction

00:23 Peter Markus's Background and Career Journey

01:26 The Birth of Kompanion Care

04:31 Innovative Technology Behind Lilia Platform

11:41 Challenges and Importance of Medical Software

15:23 Current Progress and Future Plans

22:17 Investment and Market Strategy

37:28 Conclusion and Final Thoughts

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Péter Márkus: https://www.linkedin.com/in/pmarkus/

Kompanion Care: https://www.kompanioncare.com/

Inside Europe, a new type of hospital is emerging. In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter sit down with Antonín Hlavinka, the innovation and digitalization lead at University Hospital Olomouc. Together, explore how one of the largest hospitals in the Czech Republic built a functioning AI ecosystem that is delivering measurable clinical impact today.

Discuss certified and experimental clinical AI tools, governance structures, telemedicine innovation, multimodal prediction engines, and real patient cases where AI detected what humans could not. This conversation highlights what investors, clinicians, and health system operators need to understand as Europe moves toward agent-driven hospital environments.

If you want a front-row look at the future of digital healthcare, this episode is essential.

Timecode:

00:00 Welcome and Introduction

00:24 Role and Responsibilities in Healthcare

01:31 Adoption of AI in Healthcare

02:27 Impact of COVID-19 on Technology Adoption

04:18 AI Applications in Hospitals

04:49 Certified vs. Experimental AI Models

07:47 AI Tools in Use

14:05 Innovation and Project Management

21:41 Introduction to AI in Radiology

22:10 The Evolution of AI in Healthcare

22:55 Challenges and Rapid Developments

23:30 Microsoft's Game-Changing AI Model

24:42 AI in Medical Practice

27:41 AI in Education

28:55 Balancing AI and Human Cognition

30:55 AI's Impact on Healthcare Workforce

33:30 Global Perspectives on AI Adoption

36:42 Future of AI in Hospitals

39:03 Collaborating with Startups and Innovators

40:33 Conclusion and Future Prospects

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Antonín Hlavinka: https://www.linkedin.com/in/anton%C3%ADn-hlavinka-b045754b/
Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

Can artificial intelligence bring us closer instead of pulling us apart?

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Vassili Le Moigne, founder of InTouch, about how AI voice technology is transforming elder care across 89 countries.

Together, they explore how scalable empathy, data ethics, and thoughtful design can redefine how we care for aging populations without losing the human touch.

Topics covered:

• The origin of InTouch and its mission to reduce loneliness
  

• Voice AI and cognitive engagement for seniors
  

• GDPR, data ethics, and protecting user trust
  

• The economics of aging and independent living
  

• The business of empathy in global health innovation
  

Timecode:

00:00 Starting the Call: A Busy Morning

03:00 Introducing Vassili: Background and Journey

04:51 The Birth of InTouch: Inspiration and Development

08:07 How InTouch Works: Features and Benefits

10:46 Global Reach and Compliance

16:47 Real-Life Impact: Testimonials and Feedback

19:36 Different Approaches for Alzheimer's Patients

21:06 Future Plans and Global Expansion

22:45 Addressing Loneliness Beyond Seniors

23:47 Technical Challenges and Solutions

24:55 Ethical Choices in Voice Selection

25:28 Market Differences: Europe vs. USA

27:58 Cultural Insights and Language Adaptations

30:36 Mentoring and Advice for Startups

34:17 Concluding Thoughts on InTouch

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Vassili Le Moigne: https://www.linkedin.com/in/vassililemoigne/

Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/